From Medscape Diabetes & Endocrinology

Coverage from the

American Diabetes Association (ADA) 83rd Scientific Sessions

June 22 - 26, 2023; San Diego, California and virtual

June 22 - 26, 2023 San Diego, California and virtual

ADA 2023 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells Engraftment of Vertex Pharmaceutical's VX-880 stem cell–derived islets has now been achieved in six patients, two of whom are insulin-independent at 1 year.
Medscape Medical News, July 3, 2023
ADA 2023 Triple Agonist Retatrutide Hits New Weight-Loss Highs Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair of early studies.
Medscape Medical News, June 26, 2023
ADA 2023 OASIS and PIONEER PLUS Support High-Dose Oral Semaglutide Higher doses of oral semaglutide (25 mg and 50 mg) seem to be effective in type 2 diabetes and obesity, improving upon results obtained with currently approved maximum dose of oral semaglutide 14 mg daily.
Medscape Medical News, June 25, 2023

Conference News

ADA 2023 COORDINATE-Diabetes: a 'Wake-Up Call' for Many Specialties
Medscape Medical News, July 3, 2023
ADA 2023 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells
Medscape Medical News, July 3, 2023
ADA 2023 Survodutide Impresses in Phase 2 Weight-Loss Trial
Medscape Medical News, June 30, 2023
ADA 2023 Once-Weekly Basal Insulin Nears Market for Type 2 Diabetes
Medscape Medical News, June 27, 2023
ADA 2023 ADA: Screen All With Type 2 Diabetes for Fatty Liver Disease
Medscape Medical News, June 26, 2023
ADA 2023 Triple Agonist Retatrutide Hits New Weight-Loss Highs
Medscape Medical News, June 26, 2023
ADA 2023 OASIS and PIONEER PLUS Support High-Dose Oral Semaglutide
Medscape Medical News, June 25, 2023

ADA 2023 Tackle Education and Mindset to Reduce Diabetes Distress
Medscape Medical News, June 25, 2023
ADA 2023 Kids With T2D Face Dire Complications as Young Adults
Medscape Medical News, June 25, 2023
ADA 2023 New Oral GLP-1 Agonist for Obesity, Type 2 Diabetes
Medscape Medical News, June 24, 2023
ADA 2023 'Striking' Benefit of Lipid Lowering in Primary Prevention
Medscape Medical News, June 24, 2023
ADA 2023 Cagrilintide With Semaglutide: A Way to Prevent Diabesity?
Medscape Medical News, June 24, 2023
ADA 2023 SURMOUNT-2: Tirzepatide Rings Up Major Weight Loss in T2D
Medscape Medical News, June 23, 2023
ADA 2023 Obesity Takes Center Stage at Slimmed-Down Diabetes Meeting
Medscape Medical News, June 20, 2023

Medscape Diabetes© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Who Benefits From Continuous Glucose Monitoring?
Kevin Fernando, MBChB, MSc
Bempedoic Acid: A Statin-Intolerance Savior?
Kevin Fernando, MBChB, MSc
Tirzepatide: Therapeutic Titan or Costly Cure?
Kevin Fernando, MBChB, MSc
Beta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?
Anne L. Peters, MD

Popular News From ADA 2022

Tirzepatide Powers 'Unprecedented' Weight Loss in Obesity Trial The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.
Medscape Medical News, Jun 04, 2022
'Remission Is Possible' for Patients With Type 2 Diabetes In a small study conducted in India, most patients had remission type 2 diabetes at 6 months with an intervention that included a smart app that collected data and provided lifestyle advice.
Medscape Medical News, Jun 06, 2022
Self-Injury and Suicide 'All Too Common' in Type 1 Diabetes 'With a multipronged approach to awareness, education, and identification, we have the opportunity to intervene on the link between suicide and diabetes,' says the founder of an advocacy group.
Medscape Medical News, Jun 09, 2022

Previous Coverage